Edmond de Rothschild Investment Partners invests in Sanifit Laboratoris S.L.

Private Equity - 8/9/2015

Financing will advance Sanifit’s lead drug candidate through phase IIb as a treatment for cardiovascular diseases linked to calcification.

Palma de Mallorca, Spain, September 8, 2015 - Laboratoris Sanifit S.L., a clinical-stage
biopharmaceutical company, today announces that it has raised €36.6M ($41.3M) in a Series
C financing round. The company is focused on the development of SNF472, an experimental
drug for the treatment of cardiovascular diseases linked to calcification in patients with End
Stage Renal Disease (ESRD) undergoing haemodialysis.

The investment was led by Ysios Capital and supported by a substantial syndicate of new
investors including Lundbeckfond Ventures, Forbion Capital Partners, Gilde Healthcare,
Edmond de Rothschild Investment Partners, “la Caixa” and BaxterVentures. Existing
shareholders also supported the series C round.

Sanifit also announces the appointment of Dr. Russell Greig as chairman of the board of
directors. Dr. Greig worked at GSK for nearly three decades, most recently as president of SR
One, GSK's Corporate Venture Group. Prior to joining SR One, he served as president of GSK's. Pharmaceuticals International and was on the corporate executive team from 2003 to 2008.

This round of fundraising will enable Sanifit to advance its lead drug candidate, SNF472,
through phase IIb proof of concept for the treatment of cardiovascular diseases linked to
calcification in ESRD and to complete phase II/III for calciphylaxis.

ESRD patients treated with dialysis experience higher rates of serious cardiovascular adverse
events and mortality as a consequence of accelerated progression of cardiovascular
calcification. Half of the mortality in dialysis patients is from cardiovascular complications.
Calciphylaxis is the most severe form of cardiovascular calcification. It is a devastating rare
disease that affects up to 4% of dialysis patients and has an overall mortality rate of about
80%. There are approximately 2.5 million dialysis patients worldwide with no effective
treatment for this medical condition. ESRD represents a market opportunity of over €2Bn

SNF472 has shown significant efficacy data in more than 20 preclinical studies. It has also
shown excellent safety and tolerability in a phase Ia clinical trial in healthy volunteers. SNF472 is currently concluding a phase Ib/IIa pharmacology study in haemodialysis patients.

“We are delighted to have attracted such high profile investors to our company,” said Joan
Perelló, CEO of Sanifit. “This funding will help SNF472 to address clear unmet medical needs
and will help to change the lives of patients with cardiovascular complications in the field of

“We were excited to have the opportunity to participate in this financing,” said Joël Jean-
Mairet, managing partner of Ysios Capital. “Sanifit is developing a first-in-class drug with a
unique mechanism of action that can improve patient outcomes and positively impact patient lives. This is a pivotal moment to be investing in a company focused on a condition with such an attractive market opportunity.”

 “This is an exciting and attractive opportunity to develop a new drug, SNF472, for two
underserved and life threatening conditions, ESRD and calciphylaxis,” said Russell Greig,
newly appointed chairman of Sanifit, “The company has already made significant progress
and with the support of some of Europe’s top VC Funds, it is well positioned to make
substantial and rapid progress in both these areas of pronounced unmet medical need.”